Kevin Thierry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin Thierry has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Ana Hennino
Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, F-69373 Lyon, France
3 shared publications - Hector Hernandez-Vargas
Cancer Research Center of Lyon (CRCL) INSERM 1052, CNRS 5286, Lyon, France
2 shared publications - Philippe Bertolino
Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Claude Bernard University, Lyon, France
2 shared publications Sophie Bachy
Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
2 shared publications- Zhichong Wu
Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
2 shared publications Berkan Savas
Tumor Escape, Resistance and Immunity, Cancer Research Center of Lyon, UMR INSERM 1052, CNRS 5286, Lyon F-69373, France
1 shared publication
Latest Publications
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle du compartiment stromal et des macrophages dans le cancer du pancréas
The role of the stromal compartment and macrophages in pancreatic cancer: L’adénocarcinome canalaire pancréatique est associé à une réaction stromale très importante puisqu'elle représente jusqu’à 90% du volume tumoral. La contribution du stroma tumoral à l’évolution du cancer a été décrite ces dernières années à la fois chez l’Homme et chez la souris en l’identifiant comme un nouvel acteur important dans l’initiation et la progression néoplasique. L’activation des cellules du stroma ainsi que le recrutement des cellules immunitaires contribuent à l’immunosuppression et à la résistance au thérapie dans le cancer du pancréas portant le taux de survie sur 5 ans à moins de 10%. Parmi les cellules immunitaires les plus importantes se trouvent les macrophages et les lymphocytes T CD8. L’objectif principal de cette étude est de déterminer le rôle de la communication entre le compartiment stromal et les macrophages ainsi que les conséquences sur la réponse immunitaire antitumoral dans le cancer du pancréas. La première partie de cette thèse a permis l’identification d’une population stromal ayant des caractéristique souche et pericytaire appelé PeSC. Nous montrons que cette populations permet d’induire une résistance au traitement anti-PD-1 via le recrutement de cellules immunitaire suppressive myéloïdes. Dans une deuxième partie, nous montrons qu’une sous population de macrophages présent dans l’environnement tumoral ; les macrophages CD169+ peuvent être différencié par les PeSC à la fois in vivo et in vitro. Enfin, nous montrons que les macrophages CD169+ sont nécessaire au recrutement des lymphocytes T CD8+ au sein de l’environnement tumoral mais sont également nécessaire à la mise en place de la complexité stromal. Enfin, dans la troisième partie de cette étude, nous mettons en évidence que la complexité stromal via la rigidité tissulaire peut induire une communication entre les cellules cancéreuse et les fibroblaste de manière dépendante à la signalisation PDGF. Pour terminer, nous montrons pour la première fois que cibler cette signalisation permet de réduire l’agressivité de la tumeur. En conclusion, cette thèse étudie de manière large le rôle de chacun des acteurs stromal dans le cancer du pancréas et montrent qu’une multitude de communication a lieu au cours de la progression de la maladie entre ces acteurs.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle du compartiment stromal et des macrophages dans le cancer du pancréas
The role of the stromal compartment and macrophages in pancreatic cancer: L’adénocarcinome canalaire pancréatique est associé à une réaction stromale très importante puisqu'elle représente jusqu’à 90% du volume tumoral. La contribution du stroma tumoral à l’évolution du cancer a été décrite ces dernières années à la fois chez l’Homme et chez la souris en l’identifiant comme un nouvel acteur important dans l’initiation et la progression néoplasique. L’activation des cellules du stroma ainsi que le recrutement des cellules immunitaires contribuent à l’immunosuppression et à la résistance au thérapie dans le cancer du pancréas portant le taux de survie sur 5 ans à moins de 10%. Parmi les cellules immunitaires les plus importantes se trouvent les macrophages et les lymphocytes T CD8. L’objectif principal de cette étude est de déterminer le rôle de la communication entre le compartiment stromal et les macrophages ainsi que les conséquences sur la réponse immunitaire antitumoral dans le cancer du pancréas. La première partie de cette thèse a permis l’identification d’une population stromal ayant des caractéristique souche et pericytaire appelé PeSC. Nous montrons que cette populations permet d’induire une résistance au traitement anti-PD-1 via le recrutement de cellules immunitaire suppressive myéloïdes. Dans une deuxième partie, nous montrons qu’une sous population de macrophages présent dans l’environnement tumoral ; les macrophages CD169+ peuvent être différencié par les PeSC à la fois in vivo et in vitro. Enfin, nous montrons que les macrophages CD169+ sont nécessaire au recrutement des lymphocytes T CD8+ au sein de l’environnement tumoral mais sont également nécessaire à la mise en place de la complexité stromal. Enfin, dans la troisième partie de cette étude, nous mettons en évidence que la complexité stromal via la rigidité tissulaire peut induire une communication entre les cellules cancéreuse et les fibroblaste de manière dépendante à la signalisation PDGF. Pour terminer, nous montrons pour la première fois que cibler cette signalisation permet de réduire l’agressivité de la tumeur. En conclusion, cette thèse étudie de manière large le rôle de chacun des acteurs stromal dans le cancer du pancréas et montrent qu’une multitude de communication a lieu au cours de la progression de la maladie entre ces acteurs.
- Open Access
- 30 October 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (12) , 3033-3056
Fibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas
A hallmark feature of pancreatic ductal adenocarcinoma (PDAC) is massive intratumoral fibrosis, designated as desmoplasia. Desmoplasia is characterized by the expansion of cancer-associated fibroblasts (CAFs) and a massive increase in extracellular matrix (ECM). During fibrogenesis, distinct genes become reactivated specifically in fibroblasts, e.g., the disintegrin metalloprotease, ADAM12 . Previous studies have shown that immunotherapeutic ablation of ADAM12 + cells reduces fibrosis in various organs. In preclinical mouse models of PDAC, we observe ADAM12 expression in CAFs as well as in tumor cells but not in healthy mouse pancreas. Therefore, we tested prophylactic and therapeutic vaccination against ADAM12 in murine PDAC and observed delayed tumor growth along with a reduction in CAFs and tumor desmoplasia. This is furthermore associated with vascular normalization and alleviated tumor hypoxia. The ADAM12 vaccine induces a redistribution of CD8 + T cells within the tumor and cytotoxic responses against ADAM12 + cells. In summary, vaccination against the endogenous fibroblast target ADAM12 effectively depletes CAFs, reduces desmoplasia and delays the growth of murine PDACs. These results provide proof-of-principle for the development of vaccination-based immunotherapies to treat tumor desmoplasia.
- 30 October 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (12) , 3033-3056
Open AccessFibrolytic vaccination against ADAM12 reduces desmoplasia in preclinical pancreatic adenocarcinomas
A hallmark feature of pancreatic ductal adenocarcinoma (PDAC) is massive intratumoral fibrosis, designated as desmoplasia. Desmoplasia is characterized by the expansion of cancer-associated fibroblasts (CAFs) and a massive increase in extracellular matrix (ECM). During fibrogenesis, distinct genes become reactivated specifically in fibroblasts, e.g., the disintegrin metalloprotease, ADAM12 . Previous studies have shown that immunotherapeutic ablation of ADAM12 + cells reduces fibrosis in various organs. In preclinical mouse models of PDAC, we observe ADAM12 expression in CAFs as well as in tumor cells but not in healthy mouse pancreas. Therefore, we tested prophylactic and therapeutic vaccination against ADAM12 in murine PDAC and observed delayed tumor growth along with a reduction in CAFs and tumor desmoplasia. This is furthermore associated with vascular normalization and alleviated tumor hypoxia. The ADAM12 vaccine induces a redistribution of CD8 + T cells within the tumor and cytotoxic responses against ADAM12 + cells. In summary, vaccination against the endogenous fibroblast target ADAM12 effectively depletes CAFs, reduces desmoplasia and delays the growth of murine PDACs. These results provide proof-of-principle for the development of vaccination-based immunotherapies to treat tumor desmoplasia.
- Open Access
- 1 December 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (12) , pgad405
Stiffness-induced cancer-associated fibroblasts are responsible for immunosuppression in a platelet-derived growth factor ligand-dependent manner
Pancreatic ductal adenocarcinoma (PDAC) is associated with a vast stromal reaction that arises mainly from cancer-associated fibroblasts (CAFs) and promotes both immune escape and tumor growth. Here, we used a mouse model with deletion of the activin A receptor ALK4 in the context of the KrasG12D mutation, which strongly drives collagen deposition that leads to tissue stiffness. By ligand–receptor analysis of single-cell RNA-sequencing data, we identified that, in stiff conditions, neoplastic ductal cells instructed CAFs through sustained platelet-derived growth factor (PDGF) signaling. Tumor-associated tissue rigidity resulted in the emergence of stiffness-induced CAFs (siCAFs) in vitro and in vivo. Similar results were confirmed in human data. siCAFs were able to strongly inhibit CD8+ T-cell responses in vitro and in vivo, promoting local immunosuppression. More importantly, targeting PDGF signaling led to diminished siCAF and reduced tumor growth. Our data show for the first time that early paracrine signaling leads to profound changes in tissue mechanics, impacting immune responses and tumor progression. Our study highlights that PDGF ligand neutralization can normalize the tissue architecture independent of the genetic background, indicating that finely tuned stromal therapy may open new therapeutic avenues in pancreatic cancer.
- 1 December 2023
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 2 (12) , pgad405
Open AccessStiffness-induced cancer-associated fibroblasts are responsible for immunosuppression in a platelet-derived growth factor ligand-dependent manner
Pancreatic ductal adenocarcinoma (PDAC) is associated with a vast stromal reaction that arises mainly from cancer-associated fibroblasts (CAFs) and promotes both immune escape and tumor growth. Here, we used a mouse model with deletion of the activin A receptor ALK4 in the context of the KrasG12D mutation, which strongly drives collagen deposition that leads to tissue stiffness. By ligand–receptor analysis of single-cell RNA-sequencing data, we identified that, in stiff conditions, neoplastic ductal cells instructed CAFs through sustained platelet-derived growth factor (PDGF) signaling. Tumor-associated tissue rigidity resulted in the emergence of stiffness-induced CAFs (siCAFs) in vitro and in vivo. Similar results were confirmed in human data. siCAFs were able to strongly inhibit CD8+ T-cell responses in vitro and in vivo, promoting local immunosuppression. More importantly, targeting PDGF signaling led to diminished siCAF and reduced tumor growth. Our data show for the first time that early paracrine signaling leads to profound changes in tissue mechanics, impacting immune responses and tumor progression. Our study highlights that PDGF ligand neutralization can normalize the tissue architecture independent of the genetic background, indicating that finely tuned stromal therapy may open new therapeutic avenues in pancreatic cancer.
- Open Access
- 21 February 2023
- Published by Springer Nature in EMBO Reports
- Vol. 24 (4) , e56524
Pericyte stem cells induce Ly6G+ cell accumulation and immunotherapy resistance in pancreatic cancer
We report the identification of a cell population that shares pericyte, stromal and stemness features, does not harbor the Kras G12D mutation and drives tumoral growth in vitro and in vivo. We term these cells pericyte stem cells (PeSCs) and define them as CD45−EPCAM−CD29+CD106+CD24+CD44+ cells. We perform studies with p48‐Cre;Kras G12D (KC), pdx1‐Cre;Kras G12D ;Ink4a/Arf fl/fl (KIC) and pdx1‐Cre;Kras G12D ;p53 R172H (KPC) and tumor tissues from PDAC and chronic pancreatitis patients. We also perform single‐cell RNAseq analysis and reveal a unique signature of PeSC. Under steady‐state conditions, PeSCs are barely detectable in the pancreas but present in the neoplastic microenvironment both in humans and mice. The coinjection of PeSCs and tumor epithelial cells leads to increased tumor growth, differentiation of Ly6G+ myeloid‐derived suppressor cells, and a decreased amount of F4/80+ macrophages and CD11c+ dendritic cells. This population induces resistance to anti‐PD‐1 immunotherapy when coinjected with epithelial tumor cells. Our data reveal the existence of a cell population that instructs immunosuppressive myeloid cell responses to bypass PD‐1 targeting and thus suggest potential new approaches for overcoming resistance to immunotherapy in clinical settings.
- 21 February 2023
- Published by Springer Nature in EMBO Reports
- Vol. 24 (4) , e56524
Open AccessPericyte stem cells induce Ly6G+ cell accumulation and immunotherapy resistance in pancreatic cancer
We report the identification of a cell population that shares pericyte, stromal and stemness features, does not harbor the Kras G12D mutation and drives tumoral growth in vitro and in vivo. We term these cells pericyte stem cells (PeSCs) and define them as CD45−EPCAM−CD29+CD106+CD24+CD44+ cells. We perform studies with p48‐Cre;Kras G12D (KC), pdx1‐Cre;Kras G12D ;Ink4a/Arf fl/fl (KIC) and pdx1‐Cre;Kras G12D ;p53 R172H (KPC) and tumor tissues from PDAC and chronic pancreatitis patients. We also perform single‐cell RNAseq analysis and reveal a unique signature of PeSC. Under steady‐state conditions, PeSCs are barely detectable in the pancreas but present in the neoplastic microenvironment both in humans and mice. The coinjection of PeSCs and tumor epithelial cells leads to increased tumor growth, differentiation of Ly6G+ myeloid‐derived suppressor cells, and a decreased amount of F4/80+ macrophages and CD11c+ dendritic cells. This population induces resistance to anti‐PD‐1 immunotherapy when coinjected with epithelial tumor cells. Our data reveal the existence of a cell population that instructs immunosuppressive myeloid cell responses to bypass PD‐1 targeting and thus suggest potential new approaches for overcoming resistance to immunotherapy in clinical settings.